Literature DB >> 29269431

Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat".

Jacqueline M McBride1, Jeremy J Lim2, Tracy Burgess2, Rong Deng2, Michael A Derby2, Mauricio Maia2, Priscilla Horn2, Omer Siddiqui3, Daniel Sheinson2, Haiyin Chen-Harris2, Elizabeth M Newton2, Dimitri Fillos2, Denise Nazzal2, Carrie M Rosenberger2, Maikke B Ohlson2, Rob Lambkin-Williams4, Hosnieh Fathi4, Jeffrey M Harris2, Jorge A Tavel2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29269431      PMCID： PMC5740363          DOI： 10.1128/AAC.02034-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  8 in total

Review 1.  Experimental human influenza: observations from studies of influenza antivirals.

Authors:  Frederick G Hayden
Journal:  Antivir Ther       Date:  2012-02-03

2.  Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.

Authors:  Luis Barroso; John Treanor; Larisa Gubareva; Frederick G Hayden
Journal:  Antivir Ther       Date:  2005

3.  Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.

Authors:  Jacqueline M McBride; Jeremy J Lim; Tracy Burgess; Rong Deng; Michael A Derby; Mauricio Maia; Priscilla Horn; Omer Siddiqui; Daniel Sheinson; Haiyin Chen-Harris; Elizabeth M Newton; Dimitri Fillos; Denise Nazzal; Carrie M Rosenberger; Maikke B Ohlson; Rob Lambkin-Williams; Hosnieh Fathi; Jeffrey M Harris; Jorge A Tavel
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat.

Authors:  Sally Hunsberger; Matthew J Memoli
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.

Authors:  F G Hayden; J J Treanor; R S Fritz; M Lobo; R F Betts; M Miller; N Kinnersley; R G Mills; P Ward; S E Straus
Journal:  JAMA       Date:  1999-10-06       Impact factor: 56.272

6.  Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.

Authors:  Eleanor L Ramos; Jennifer L Mitcham; Teri D Koller; Aurelio Bonavia; Dale W Usner; Ganesh Balaratnam; Paul Fredlund; Kristine M Swiderek
Journal:  J Infect Dis       Date:  2014-10-03       Impact factor: 5.226

7.  IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo.

Authors:  David J Jackson; Heidi Makrinioti; Batika M J Rana; Betty W H Shamji; Maria-Belen Trujillo-Torralbo; Joseph Footitt; Aurica G Telcian; Alexandra Nikonova; Jie Zhu; Julia Aniscenko; Leila Gogsadze; Eteri Bakhsoliani; Stephanie Traub; Jaideep Dhariwal; James Porter; Duncan Hunt; Toby Hunt; Trevor Hunt; Luminita A Stanciu; Musa Khaitov; Nathan W Bartlett; Michael R Edwards; Onn Min Kon; Patrick Mallia; Nikolaos G Papadopoulos; Cezmi A Akdis; John Westwick; Matthew J Edwards; David J Cousins; Ross P Walton; Sebastian L Johnston
Journal:  Am J Respir Crit Care Med       Date:  2014-12-15       Impact factor: 21.405

8.  A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN-γ and IFN-λ) and Type 2 Inflammation (IL-5 and IL-13).

Authors:  Trevor T Hansel; Tanushree Tunstall; Maria-Belen Trujillo-Torralbo; Betty Shamji; Ajerico Del-Rosario; Jaideep Dhariwal; Paul D W Kirk; Michael P H Stumpf; Jens Koopmann; Aurica Telcian; Julia Aniscenko; Leila Gogsadze; Eteri Bakhsoliani; Luminita Stanciu; Nathan Bartlett; Michael Edwards; Ross Walton; Patrick Mallia; Toby M Hunt; Trevor L Hunt; Duncan G Hunt; John Westwick; Matthew Edwards; Onn Min Kon; David J Jackson; Sebastian L Johnston
Journal:  EBioMedicine       Date:  2017-03-28       Impact factor: 8.143
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.